Yes. The volatility comes from the fact that what a company invests in a drug can be multiples less than what an (anticipated working drug) is worth or deemed to be worth. If we sell or partner with a BP, keep that in mind when you hear the "price".
The market had a high view of that drug's commercial potential, as did a lot of sharp managers and scientists. Turned out wrong. Biotech is risky and the stocks are volatile.
News 
Market Data 
Discover 
